8-K filed June 14, 2023, 7:59 PM ET ticker SPRO CIK 0001701108

leadership confidence high sentiment neutral materiality 0.65

Spero Therapeutics appoints Sath Shukla as CEO, Mahadevia becomes Chairman

Spero Therapeutics, Inc.

CEO Ankit Mahadevia steps down effective Aug 1, 2023; becomes Chairman of the Board.
CFO Satyavrat 'Sath' Shukla appointed CEO and President, also joins Board.
Stephen DiPalma appointed Interim CFO, effective Aug 1, 2023.
Chairman Milind Deshpande steps down but remains director; Patrick Vink named Lead Independent Director.
Mahadevia to receive $54k/month consulting fee through Jan 2024, then $310/hour through July 2025.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Ankit Mahadevia

Chief Executive Officer and President

SPRO · Spero Therapeutics, Inc.

Effective: 2023-08-01
Successor: Satyavrat Shukla
Filed: June 14, 2023, 7:59 PM ET

Ankit Mahadevia, M.D., the Company’s Chief Executive Officer and President, determined to step down from that role, effective as of August 1, 2023

Role change

Satyavrat Shukla

Chief Executive Officer and President

SPRO · Spero Therapeutics, Inc.

Effective: 2023-08-01
Successor: Stephen J. DiPalma
Filed: June 14, 2023, 7:59 PM ET

Satyavrat Shukla, the Company’s current Chief Financial Officer and Treasurer, was appointed by the Board to serve as Chief Executive Officer and President of the Company and as a member of the Board

Appointed (interim)

Stephen J. DiPalma

Interim Chief Financial Officer and Treasurer

SPRO · Spero Therapeutics, Inc.

Effective: 2023-08-01
Successor: Satyavrat Shukla
Filed: June 14, 2023, 7:59 PM ET

Stephen J. DiPalma to be the Company’s Interim Chief Financial Officer and Treasurer to succeed Mr. Shukla

Appointed

Ankit Mahadevia

Chairman of the Board

SPRO · Spero Therapeutics, Inc.

Effective: 2023-08-01
Filed: June 14, 2023, 7:59 PM ET

Dr. Mahadevia will serve as a consultant to the Company and will continue to serve as a member of the Company’s Board of Directors (the “Board”) and will assume the role of Chairman of the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ankit Mahadevia departed as Chief Executive Officer and President at Spero Therapeutics, Inc..

Action: stepped down
Role: Chief Executive Officer and President

Exact text from the filing

Ankit Mahadevia, M.D., the Company’s Chief Executive Officer and President, determined to step down from that role, effective as of August 1, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Satyavrat Shukla was appointed as Chief Executive Officer and President at Spero Therapeutics, Inc..

Action: appointed
Role: Chief Executive Officer and President

Exact text from the filing

Satyavrat Shukla, the Company’s current Chief Financial Officer and Treasurer, was appointed by the Board to serve as Chief Executive Officer and President of the Company and as a member of the Board

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen J. DiPalma was appointed as Interim Chief Financial Officer and Treasurer at Spero Therapeutics, Inc..

Action: appointed
Role: Interim Chief Financial Officer and Treasurer

Exact text from the filing

Stephen J. DiPalma to be the Company’s Interim Chief Financial Officer and Treasurer to succeed Mr. Shukla

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ankit Mahadevia was appointed as Chairman of the Board at Spero Therapeutics, Inc..

Action: assume
Role: Chairman of the Board

Exact text from the filing

Dr. Mahadevia will serve as a consultant to the Company and will continue to serve as a member of the Company’s Board of Directors (the “Board”) and will assume the role of Chairman of the Board

View on SEC.gov

Spero Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-166543

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.